Theradiag (ALTER.PA) Stock Price
Theradiag Price
Over the last 11 years Theradiag grew revenue by 2.4% annually, reaching 13.16 M EUR. For Theradiag, the net margin of -3.7% is up versus -8.8% a few years ago.
Theradiag stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Theradiag business model & stock analysis
Frequently asked questions about Theradiag
Theradiag SA is a biotechnology company based in France. The business model of Theradiag SA primarily focuses on the development, manufacturing, and commercialization of in vitro diagnostic tests and innovative theranostics. The company specializes in personalized medicine, providing diagnostic solutions for autoimmune diseases, cancer, and infectious diseases. Theradiag SA aims to improve patient care by offering reliable tests that help healthcare professionals make informed treatment decisions. By combining diagnostics and therapeutics, Theradiag SA strives to contribute to precision medicine and enhance patient outcomes.
Theradiag SA is primarily active in the healthcare industry.
The main competitors of Theradiag SA in the market include renowned companies such as bioMérieux, Quanterix Corporation, DiaSorin, and Myriad Genetics.
Theradiag SA, a renowned company in the stock market, has a rich history and background. Established in 1987, Theradiag SA is a French in vitro diagnostics company specializing in theranostics and personalized medicine diagnostic tests. With a strong focus on innovative solutions, the company aims to improve patient care and treatment outcomes. Through strategic partnerships and continuous research and development, Theradiag has built a strong reputation for its diagnostic products, including its proprietary LISA Tracker range for monitoring biotherapies. With a commitment to advancing healthcare, Theradiag SA continues to contribute to the ever-evolving field of diagnostics.
Theradiag SA, a leading healthcare company, has successfully achieved several significant milestones. Over the years, the company has made remarkable progress in the field of in vitro diagnostics and personalized medicine. Theradiag SA has developed innovative diagnostic tools and advanced testing solutions, contributing to improved patient care and treatment outcomes. Notably, the company has launched multiple cutting-edge products that have garnered positive recognition in the medical community. Theradiag SA continues to invest in research and development, expanding its product portfolio and gaining recognition as a trusted partner in healthcare. Through these achievements, Theradiag SA demonstrates its commitment to pioneering advancements in diagnostic technologies.
Theradiag SA is primarily present in France, where it is headquartered. The company operates in various regions within France, including Paris and Montpellier. Additionally, Theradiag SA has established its presence in several international markets, such as Germany, Spain, Italy, the United Kingdom, and the Benelux countries. With its focus on specialty diagnostics, Theradiag SA has expanded its footprint to serve healthcare professionals, laboratories, and patients in these countries and regions.
Theradiag SA, a leading medical diagnostics company, represents values and a corporate philosophy centered around innovation, excellence, and patient-centric solutions. With a strong commitment to improving patient outcomes, Theradiag focuses on developing and commercializing cutting-edge diagnostics products for personalized medicine in the areas of autoimmune diseases and cancer. By leveraging advanced technologies and scientific expertise, Theradiag aims to provide healthcare professionals and patients with accurate and timely diagnostic tools, enabling early detection, optimized treatment decisions, and improved quality of life. Through collaboration, integrity, and continuous improvement, Theradiag SA strives to make a positive impact on global healthcare.
7 analysts currently rate the Theradiag stock: 0 recommend buying, 3 holding and 4 selling.
The Theradiag share (ALTER.PA) is listed on 4 stock exchanges, including: Frankfurt (4W6.F), München (4W6.MU), Paris (ALTER.PA).
Theradiag SA is a French biopharmaceutical company specializing in the development, manufacturing, and marketing of diagnostic systems and in vitro diagnostics (IVD). The company focuses on developing diagnostic tests for autoimmune diseases, infectious diseases, and cancer. The company offers a wide range of products and services aligned with its three business segments: in vitro diagnostics (IVD), immunology, and theranostics. The IVD segment is Theradiag's core business, encompassing a broad range of diagnostic tests and systems targeted towards the treatment of autoimmune diseases, infectious diseases, and cancer. Some key IVD products of Theradiag include: - LISA TRACKER: A diagnostic test that allows monitoring the effectiveness of therapy for autoimmune diseases such as Crohn's disease and ulcerative colitis. - VIDAS: An automated IVD system for diagnosing infectious diseases, including HIV, hepatitis B and C. In the immunology segment, Theradiag focuses on the development of high-quality diagnostic tests that concentrate on patients' immunity. These include: - BÜHLMAN ANA ELISA: A diagnostic test enabling the determination of autoantibodies associated with systemic autoimmune diseases. - BÜHLMAN ANCA ELISA: A diagnostic test enabling the detection of autoantibodies associated with diseases such as granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. The theranostics segment includes a wide range of innovative technologies that can be used to optimize medical treatments. These include: - TRACKER ID-MS: A technology that allows precise monitoring of drug levels in patients' blood. - TRACKER PCR: A technology used to monitor disease burden in patients with Pneumocystis pneumonia (PCP) and toxoplasmosis. Theradiag employs a customer-oriented sales strategy, directly selling its products to hospitals and clinical laboratories in France and internationally. The company also maintains partnerships with other companies and organizations to distribute and market its products globally. In the future, Theradiag plans to strengthen its R&D activities and expand its market presence by focusing on the development of innovative products and technologies to remain competitive in the global market and maintain its position as a key player in the in vitro diagnostics industry.
The revenue cannot currently be calculated for Theradiag.
The profit cannot currently be calculated for Theradiag.
The P/E ratio cannot be calculated for Theradiag at the moment.
The P/S cannot be calculated for Theradiag currently.
The Eulerpool Quality Score for Theradiag is 2/10.
The ISIN of Theradiag is FR0004197747. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Theradiag is A1J9WY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Theradiag is ALTER.PA. The ticker symbol is used to trade Theradiag shares on the stock exchange.
Theradiag stock
Theradiag Peer Group
Theradiag Ticker
Theradiag FIGI
All fundamentals and in-depth analysis of Theradiag
Our stock analysis for Theradiag stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theradiag. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.